These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
788 related articles for article (PubMed ID: 20516435)
1. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B; J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435 [TBL] [Abstract][Full Text] [Related]
2. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. Williamson SK; Crowley JJ; Lara PN; McCoy J; Lau DH; Tucker RW; Mills GM; Gandara DR; J Clin Oncol; 2005 Dec; 23(36):9097-104. PubMed ID: 16361616 [TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G; J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K; J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
6. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
8. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer. Splinter TA Semin Oncol; 1996 Dec; 23(6 Suppl 16):59-61. PubMed ID: 9007124 [TBL] [Abstract][Full Text] [Related]
10. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). Lilenbaum RC; Herndon JE; List MA; Desch C; Watson DM; Miller AA; Graziano SL; Perry MC; Saville W; Chahinian P; Weeks JC; Holland JC; Green MR J Clin Oncol; 2005 Jan; 23(1):190-6. PubMed ID: 15625373 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202 [TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. Rosell R; Gómez-Codina J; Camps C; Maestre J; Padille J; Cantó A; Mate JL; Li S; Roig J; Olazábal A N Engl J Med; 1994 Jan; 330(3):153-8. PubMed ID: 8043059 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567 [TBL] [Abstract][Full Text] [Related]
17. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646 [TBL] [Abstract][Full Text] [Related]
18. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135 [TBL] [Abstract][Full Text] [Related]
19. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422 [TBL] [Abstract][Full Text] [Related]
20. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]